Skip to content

Clinical study on the treatment of overweight/ obese polycystic ovary syndrome (PCOS) by tonifying kidney, resolving phlegm and removing blood stasis combined with Metformin

Clinical study on the treatment of overweight/ obese polycystic ovary syndrome (PCOS) by tonifying kidney, resolving phlegm and removing blood stasis combined with Metformin

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086002
Enrollment
Unknown
Registered
2024-06-24
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

Intervention group:Chinese medicine for tonifying kidney, resolving phlegm and removing blood stasis combined with Metformin
Control Group:Chinese medicine placebo for tonifying kidney, resolving phlegm and removing blood stasis combined with Metformin

Sponsors

Yueyang Hospital of Integrated Chinese and Western medicine, Shanghai University of Traditional Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.According to the diagnostic standard of Western medicine PCOS, TCM syndrome differentiation standard of phlegm-dampness block; 2.BMI>=24kg/m2; 3.Ages 18-40(including 18 and 40); 4.Agree to participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with androgen-secreting tumors, congenital adrenal cortex hyperplasia, and Cushing syndrome; 2.Patients using medications related to diseases such as insulin-dependent diabetes, Crohn's disease, leiomyoma, thyroid disorders, liver conditions, heart disease, chronic diarrhea, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, and cancer; 3.Patients with organic diseases such as congenital gonadal dysgenesis, tubal obstruction, and genital tract malformations; 4.Patients with cardiac, hepatic and renal insufficiency; 5.Persons with mental illness; 6.Pregnant or lactating women; 7.Participants in similar studies in the past three months.

Design outcomes

Primary

MeasureTime frame
Ovulation rate;

Secondary

MeasureTime frame
TCM Syndrome scoring form;Ferriman-gallwey hirsutism rating scale;Acne Pillsbury Rating Scale;Black acanthosis scoring criteria;Sex Hormones;Fasting Blood Glucose;Fasting Insulin;Insulin Resistance Index;Fasting Blood Lipids;25-OH-VitD;Ferritin;Blood routine test;Urine routine;Liver function;Renal function;electrocardiogram;

Countries

China

Contacts

Public ContactYang Cao

Yueyang Hospital of Integrated Chinese and Western medicine, Shanghai University of Traditional Chinese medicine

cindy8813966@126.com+86 137 6429 3960

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026